Kura Oncology (KURA) concentration risks

Kura Oncology's concentration risk is fundamentally structural: the company's only approved product, KOMZIFTI, is approved solely as a monotherapy for adult patients with relapsed or refractory NPM1-mutated AML — a narrow, single-product, single-indication profile that makes the entire commercial thesis dependent on one drug's continued efficacy, safety, and market uptake within that specific patient population. Layered on top is a counterparty dependency: Kura records all U.S. sales of KOMZIFTI, but shares profits and losses from U.S. commercialization equally with Kyowa Kirin. This economic arrangement means Kura's realized commercial upside from its lone product is itself split with a partner, adding a dependency-type exposure to the underlying product concentration. Together, these two exposures compound rather than offset: the single-product concentration is the more consequential of the two, since any setback to KOMZIFTI — whether regulatory, competitive, or clinical — would affect the entire company's prospects rather than one division among several. The Kyowa Kirin profit-sharing arrangement doesn't add incremental business risk so much as it caps the economic benefit Kura captures even if KOMZIFTI performs well, a distinction investors should weight when assessing upside relative to the underlying product risk.

For the engine’s reasoning on KURA’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.